Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Healius Limited ( (AU:HLS) ) has issued an update.
Macquarie Group Limited and a wide range of its controlled entities have lodged a notice that they have ceased to be substantial holders in Healius Limited. The filing, signed by Macquarie’s company secretary, formalises the change in Macquarie’s voting interest and confirms that the group no longer holds a stake large enough to be classified as substantial under Australian corporate law.
The change removes a major institutional investor from Healius’s share register, potentially altering the company’s ownership profile and investor base. While the notice does not disclose transaction specifics or rationale, the exit of a large financial group may influence market perceptions of Healius and could affect trading dynamics and future engagement with institutional shareholders.
The most recent analyst rating on (AU:HLS) stock is a Sell with a A$0.49 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.
More about Healius Limited
Healius Limited is an Australian healthcare company listed on the ASX under the ticker HLS.AX. It operates in the medical services sector, providing diagnostic and related healthcare services across Australia to patients, clinicians and healthcare facilities.
Average Trading Volume: 3,377,282
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$377.6M
Find detailed analytics on HLS stock on TipRanks’ Stock Analysis page.